Page 7 - Keith Pinder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In preclinical studies, Uttroside-B was up to 10-times more potent against HCC cells than Sorafinib, the standard of care drug at the time. As an Orphan Drug, Uttroside-B may benefit from a seven-year market exclusively following m...

Published: Jan 26, 2021   NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Q Biomed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma" is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the tech...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to ... Predictive Oncology Inc.January 14, 2021 GMT EAGAN, Minn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter has sold media to two top research medical centers, one in New...

Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment Strontium89 Now Reimbursed in All Treatment Settings News provided by Share this article NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that the Centers for Medicare and Medicaid Services (CMS) updated the Outpatient Prospective Payment System (OPPS) reimbursement rate for its FDA approved non-opioid metastatic bone pain drug Strontium89 (Strontium Chloride Sr-89 Injection, USP) on January 3, 2021. The update ensures all...

Q BioMed Updates Shareholders at Year End Company Expects Several Milestones as Momentum Builds for 2021 News provided by Share this article Dear Fellow Shareholders, As 2020 draws to a close, we join the rest of the world in looking forward to a new year with new beginnings and hope for a quick return to whatever the new normal will be. Leaving behind the constant threat of lockdowns and the interruption the COVID-19 pandemic has had on our lives will be a welcome change. With that in mind we acknowledge that 2020 was not the year we promised and feel even more committed to achieving our ...